​Omada Health pulled off something that was, especially at the time, highly unusual in the ever-burgeoning yet still-fledgling digital health space: In 2016, the company scored federal government reimbursements for its diabetes prevention program. It’s continued to grow since then and shared results from nine different peer-reviewed studies noting significant results for diabetes, cardiovascular disease, and obesity patients—a case study in how at least one company in the sphere is using data to try and fuel real world patient outcomes.

“It’s not about the data itself, it’s how you use it,” Omada co-founder and CEO Sean Duffy told Fortune in an interview earlier this year, echoing many of the chief executives and industry observers we spoke with for our recent feature on big data and AI in medicine. “The types of data that are going to be most useful going forward is the ‘in between’ data—what happens between actual health care visits,” he adds.

Read More: ​http://fortune.com/2018/04/17/diabetes-big-data-omada-health/

REDWOOD CITY, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that five posters will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 14-18, 2018, in Chicago. Among the presentations will be preclinical data for OncoMed's novel anti-TIGIT (OMP-313M32) immuno-oncology program, which is currently in a Phase 1a single-agent clinical study. Preclinical data for OncoMed's differentiated clinical-stage GITRL-Fc (OMP-336B11) program will also be featured. In addition, preclinical immuno-oncology data for OncoMed's Wnt antagonist vantictumab (anti-FZD, OMP-18R5) in combination with immune checkpoint inhibitors will be presented.

Read More: http://www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1063140

Plan helps accounts choose the right solutions to keep employees healthy and lower health care costs

BOSTON, April 2, 2018 /PRNewswire-USNewswire/ -- Digital health is a hotbed for innovation, with venture capitalists spending nearly $5 billion in the space last year (think FitBits, Smart Scales, and wellness apps). With the constant surge in new products and services entering the market, it's often difficult for companies to know which solutions can best address their employees' unique health challenges. That's why Blue Cross Blue Shield of Massachusetts (Blue Cross) is introducing the Emerging Solutions platform to curate market-leading health solutions and provide advice to employer customers on which solutions could best help improve their employees' health. 

Emerging Solutions is available to self-insured accounts with 1,000+ employees starting July 1, 2018. Currently, our offering includes nationally recognized solutions for diabetes prevention and management as well as fertility, pregnancy, and parenting—key health issues that are of interest to our accounts. These solutions are:

Livongo, the leading consumer digital health platform that empowers people with chronic conditions like diabetes to live better and healthier lives.

Omada, a digital provider of the Diabetes Prevention Program, delivering the tools and support for participants to improve lifestyle, behavior, and overall health.

Ovia Health, which uses technology and predictive coaching to support women from preconception and pregnancy through return-to-work and parenthood.​
​
​Read More: https://www.prnewswire.com/news-releases/blue-cross-blue-shield-of-massachusetts-launches-portfolio-of-digital-health-solutions-300622601.html